Bruce C. Cozadd Sells 3,000 Shares of Jazz Pharmaceuticals plc – (JAZZ) Stock

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 3,000 shares of the stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $150.00, for a total transaction of $450,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Jazz Pharmaceuticals plc – (NASDAQ JAZZ) opened at $149.71 on Thursday. Jazz Pharmaceuticals plc – has a one year low of $117.16 and a one year high of $163.75. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63. The firm has a market cap of $8,980.00, a P/E ratio of 24.66, a PEG ratio of 0.80 and a beta of 0.97.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $2.93 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.40. Jazz Pharmaceuticals had a net margin of 23.58% and a return on equity of 22.92%. sell-side analysts anticipate that Jazz Pharmaceuticals plc – will post 9.76 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the stock. FMR LLC boosted its position in Jazz Pharmaceuticals by 11.4% during the 2nd quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock worth $1,289,159,000 after buying an additional 849,348 shares during the period. Vanguard Group Inc. boosted its position in Jazz Pharmaceuticals by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company’s stock worth $727,308,000 after buying an additional 153,908 shares during the period. Bank of New York Mellon Corp boosted its position in Jazz Pharmaceuticals by 7.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,486,426 shares of the specialty pharmaceutical company’s stock worth $217,390,000 after buying an additional 105,838 shares during the period. Westfield Capital Management Co. LP boosted its position in Jazz Pharmaceuticals by 8.7% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,438,481 shares of the specialty pharmaceutical company’s stock worth $210,378,000 after buying an additional 115,217 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Jazz Pharmaceuticals by 3.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,201,500 shares of the specialty pharmaceutical company’s stock worth $186,833,000 after buying an additional 40,537 shares during the period. Institutional investors and hedge funds own 91.26% of the company’s stock.

A number of equities research analysts have issued reports on JAZZ shares. BMO Capital Markets reiterated a “buy” rating and set a $196.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, September 20th. UBS Group reiterated a “buy” rating and set a $172.00 price objective (down from $175.00) on shares of Jazz Pharmaceuticals in a research note on Monday, September 25th. Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, September 28th. They set a “neutral” rating and a $165.00 price objective on the stock. Morgan Stanley started coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, October 5th. They set an “equal weight” rating and a $155.00 price objective on the stock. Finally, FBR & Co started coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $206.00 price objective on the stock. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company. Jazz Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $181.48.

TRADEMARK VIOLATION NOTICE: This article was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3143955/bruce-c-cozadd-sells-3000-shares-of-jazz-pharmaceuticals-plc-jazz-stock.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.